Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2025-11-03 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is HKEX Form FF301, a mandatory monthly return under Chapter 19B of the Hong Kong Listing Rules reporting movements in authorised share capital, issued shares, share options, convertibles, etc. It is a regulatory submission rather than a narrative report (e.g., 10-K, IR) or specific event announcement (e.g., dividend, M&A, board change). It does not announce a new report publication; it is the report itself. There is no fitting category for a recurring listing rule return except the fallback for miscellaneous regulatory filings. Therefore, it is classified as a Regulatory Filing (RNS).
2025-11-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (FF305) filed under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares and treasury shares, including an on‐market repurchase of its own shares and sale of treasury shares. This falls squarely under a "Transaction in Own Shares" filing rather than a dividend, board change, financing update, or full report. It is not an announcement of a report but the actual disclosure of share repurchases and treasury share transactions. Therefore, the correct classification is POS.
2025-10-31 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS A BEST-IN-CLASS ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED AMYLIN RECEPTOR AGONIST, ASC36, FOR CLINICAL DEVELOPMENT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement on the Hong Kong Stock Exchange about a new clinical development candidate (ASC36), preclinical study results, and a conference call notice. It does not present financial results (so not ER, IR, or 10-K), nor is it a formal investor presentation, proxy solicitation, management change, share issue, or legal notice. It is a miscellaneous regulatory announcement of business development, fitting the fallback category “Regulatory Filings (RNS).”
2025-10-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is the Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing on-market repurchases of the issuer’s own shares and changes in treasury share balances. It is not an earnings release, annual report, or audit report but a regulatory disclosure of share buybacks (i.e., transactions in the issuer’s own shares). Therefore, it falls under the “Transaction in Own Shares” category (Code: POS).
2025-10-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules, detailing changes in issued shares and repurchase of shares, including treasury share transactions and on-market repurchases. It is not an announcement of a report publication, nor an earnings release, M&A or AGM material. It specifically reports the company’s share buybacks and treasury share transactions, which falls under Transaction in Own Shares.
2025-10-27 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS TO PRESENT STUDY RESULTS OF ASC30 ORAL TABLET, ASC30 INJECTION, AND COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Ascletis Pharma regarding poster presentations at an external scientific conference (ObesityWeek® 2025). It is not an AGM material, earnings release, regulatory or financial report, nor does it detail management changes, dividends, share transactions, or filings like 10-K, IR, ER, etc. It does not present an investor slide deck but simply notifies shareholders of upcoming research presentations. As it does not fit any other specific category, it falls into the fallback category for miscellaneous corporate announcements (Regulatory Filings).
2025-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.